1. Primary end point of the ANZICS low-dose dopamine trial
Primary end point of the ANZICS low-dose dopamine trial. In the ANZICS trial, there was no difference between low-dose dopamine and placebo in the primary outcome measure, which was peak serum creatinine attained during trial drug infusion. Peak urea and increments from baseline of creatinine and urea were also similar in the placebo and dopamine groups. (Data from Murray PT. Use of dopaminergic agents for renoprotection in the ICU. Yearbook of Intensive Care and Emergency Medicine. Springer-Verlag; 2003 and Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. December 23-30, 2000;356(9248): )
Source: Acute Kidney Injury, Principles of Critical Care, 4e
Citation: Hall JB, Schmidt GA, Kress JP. Principles of Critical Care, 4e; 2015 Available at: Accessed: December 30, 2017
Copyright © 2017 McGraw-Hill Education. All rights reserved